450 related articles for article (PubMed ID: 28819719)
1. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
[TBL] [Abstract][Full Text] [Related]
2. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
Al Nakouzi N; Le Moulec S; Albigès L; Wang C; Beuzeboc P; Gross-Goupil M; de La Motte Rouge T; Guillot A; Gajda D; Massard C; Gleave M; Fizazi K; Loriot Y
Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
[TBL] [Abstract][Full Text] [Related]
3. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
[TBL] [Abstract][Full Text] [Related]
4. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):576-583. PubMed ID: 29275450
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Sequential Treatment With Androgen Receptor-Targeted Agent Followed by Another Androgen Receptor-Targeted Agent Versus Androgen Receptor-Targeted Agent Followed by Docetaxel in Chemotherapy-Naive Patients With Metastatic Castration-Resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2017 Dec; 15(6):e1073-e1080. PubMed ID: 28826931
[TBL] [Abstract][Full Text] [Related]
6. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
[TBL] [Abstract][Full Text] [Related]
7. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
8. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
[TBL] [Abstract][Full Text] [Related]
9. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
[TBL] [Abstract][Full Text] [Related]
10. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
[TBL] [Abstract][Full Text] [Related]
11. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
[TBL] [Abstract][Full Text] [Related]
13. Impact of Prior Use of an Androgen Receptor-Axis-Targeted (ARAT) Agent With or Without Subsequent Taxane Therapy on the Efficacy of Another ARAT Agent in Patients With Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Apr; 15(2):e217-e222. PubMed ID: 27522450
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel.
Shiota M; Nakamura M; Yokomizo A; Tomoda T; Sakamoto N; Seki N; Hasegawa S; Yunoki T; Harano M; Kuroiwa K; Eto M
Anticancer Res; 2020 Jan; 40(1):335-339. PubMed ID: 31892584
[TBL] [Abstract][Full Text] [Related]
15. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
17. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study.
Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]